Pharmaceutical Development and Characteristics of Orally Disintegrating Tablets with Dihydroquercetin Formulation Modifications
Scientia Pharmaceutica · 09.07.2026 · 94 (3) · 56
DOI: 10.3390/scipharm94030056 ↗Kurz gefasst
Fachartikel in der Zeitschrift Scientia Pharmaceutica, online erschienen am 09.07.2026. Verfasst von Roman P. Terekhov und 6 weiteren Autor:innen. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation.
Abstract (Originalsprache)
Oral diseases cause a wide range of difficulties for patients. The natural bioactive compound dihydroquercetin (DHQ), which demonstrates regenerative, anti-inflammatory, antioxidative, and antibacterial effects, is of interest for their treatment. The combination of DHQ and l-lysine DHQ is “very easily soluble”. The aim of this study is to compare orally disintegrating tablets based on raw DHQ and on the DHQ-l-lysine composition. Following the guidelines outlined in the ICH Q8 (R2) standard, a fundamental quality target product profile and critical quality attributes were established. The Sediment Delivery Model (SeDeM) method was used to evaluate the substance suitability for direct compression. Quantitative analysis of the DHQ release was carried out by high-performance liquid chromatography, and infrared (IR) spectroscopy was performed using the attenuated total reflection technique without any prior sample preparation. The DHQ-l-lysine composition shows improved dimensions (4.12) and flowability (4.96). The release rate constants (Krelease) were 8.14 and 3.61%/min, while the half-release periods (t50%) were 6.14 and 13.85 min for tablets with DHQ (TF1) and DHQ-l-lysine compositions (TF2), respectively. The difference factor (f1) and similarity factor (f2) were 23.43% and 43.37%, respectively. The tablet manufacture had a critical impact on the characteristics of the IR spectra (the r values −0.8785 and 0.5474 for TF1 and TF2). The conducted study demonstrates the promise of using DHQ-l-lysine composition for developing effective dosage forms with improved technological characteristics and controlled release of the active substance.
Förderung
- Russian Science Foundation
Zitieren
APA
Terekhov, R. P., Korochkina, M. D., Krivozubova, E. V., Evzikov, G. Y., Svotin, A. A., Anurova, M. N., & Selivanova, I. A. (2026). Pharmaceutical Development and Characteristics of Orally Disintegrating Tablets with Dihydroquercetin Formulation Modifications. Scientia Pharmaceutica, 94(3), 56. https://doi.org/10.3390/scipharm94030056
Vancouver
Terekhov RP, Korochkina MD, Krivozubova EV, Evzikov GY, Svotin AA, Anurova MN, et al. Pharmaceutical Development and Characteristics of Orally Disintegrating Tablets with Dihydroquercetin Formulation Modifications. Scientia Pharmaceutica. 2026;94(3):56. doi:10.3390/scipharm94030056
BibTeX
@article{Terekhov2026,
author = {Terekhov, Roman P. and Korochkina, Maria D. and Krivozubova, Elizaveta V. and Evzikov, Grigory Yu. and Svotin, Artem A. and Anurova, Maria N. and Selivanova, Irina A.},
title = {Pharmaceutical Development and Characteristics of Orally Disintegrating Tablets with Dihydroquercetin Formulation Modifications},
journal = {Scientia Pharmaceutica},
year = {2026},
volume = {94},
number = {3},
pages = {56},
doi = {10.3390/scipharm94030056}
}
EUVIMED